Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
PGHLNSEProcter & Gamble Health Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 16 Sept, 2025 · 17:09 IST

CFO Lokesh Chandak resigns; Shashank Srowthy named successor

Cfo ResignedKmp ResignedManagement Changes View source PDFExplain this filing

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.5%Reaction day
₹6360.00
prior close
₹6399.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%-1.1% vs market
Pharmaceuticals peers, median of 154sector+0.1%-0.6% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.8
10m
-0.4
15m
+0.0
30m
-0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.5+0.6-1.1+0.1-0.6
Next day
-1.3+0.4-1.7+0.3-1.6
2d
+0.3+0.8-0.4+0.2+0.2
3d
-1.7+0.0-1.7-0.6-1.1
4d
-1.0-0.3-0.7-0.9-0.1
5d
-1.3-0.6-0.7-1.1-0.3
1w
-1.1-3.8+2.7-4.0+2.9
15d
-4.1-2.9-1.1-3.5-0.6
1m
-1.8-2.9+1.1-4.1+2.3
2m
-6.9-1.5-5.4-4.9-2.0
3m
-9.9-8.1-1.9-8.0-1.9
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On September 16, 2025, Lokesh Chandak resigned as Director and Chief Financial Officer effective September 30, 2025, after joining a new P&G finance role. Shashank Srowthy, a P&G finance professional with 14 years of experience, was appointed CFO and Additional Executive Director effective October 1, 2025, subject to government and shareholder approvals.

Likely market impact

This is a planned internal finance leadership transition, so disruption is likely limited. The new CFO starts October 1, 2025, subject to final approvals.